Insulin therapy, delivered via subcutaneous (SC) injections or continuous subcutaneous insulin infusion (CSII) systems, remains indispensable, particularly in individuals with T1DM and those with progressive or inadequately controlled T2DM
In many ways, we laid a good foundation for future work, Benham said
Retatrutide is an investigational once-weekly triple agonist that targets GLP-1, GIP, and glucagon receptors
Why GLP-1 is the Target of Modern Weight Loss Medications The global obesity epidemic has driven intense research into therapeutic strategies for weight loss
Keystone Infectious Diseases Medical Director, Dr
For example, some GLP-1R agonists primarily activate the insulin secretion signaling pathway, whereas others focus more on promoting insulin sensitivity or inhibiting glucagon secretion (Deganutti et al., 2022)